{"id":"NCT01468584","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients","officialTitle":"A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Subjects With Genotype 2 Hepatitis C, Who Did Not Respond to Previous Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2013-09","completion":"2013-09","firstPosted":"2011-11-09","resultsPosted":"2014-11-03","lastUpdate":"2014-11-03"},"enrollment":10,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C"],"interventions":[{"type":"DRUG","name":"MP-424 (generic name:Telaprevir)","otherNames":[]},{"type":"DRUG","name":"Ribavirin","otherNames":[]},{"type":"DRUG","name":"Peginterferon alfa-2b","otherNames":[]}],"arms":[{"label":"MP-424","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who did not respond to previous treatment.","primaryOutcome":{"measure":"Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","timeFrame":"After 24 weeks of follow-up","effectByArm":[{"arm":"MP-424","deltaMin":50,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["25196718"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":["Anaemia","Injection site reaction","Blood bilirubin increased","Decreased appetite","Malaise"]}}